Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Apalutamide

FDA-approved product (tablet, oral), marketed as Apalutamide, Erleada.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Apalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Anti-androgens
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Apalutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Apalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

    NCT06473259 · start 2016-12-16

    Registered record
    Registry ID
    NCT06473259
    Conditions
    Prostate Cancer; Hormone Sensitive Prostate Cancer; Metastatic Tumor
    Interventions
    Docetaxel; Apalutamide Oral Tablet; Enzalutamide Oral Tablet; Abiraterone acetate tablets; Darolutamide Oral Tablet; radiotherapy; Triptorelin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2016-12-16
    Completion
    2028-12
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Hormone Sensitive Prostate Cancer; Metastatic Tumor
    InterventionDocetaxel; Apalutamide Oral Tablet; Enzalutamide Oral Tablet; Abiraterone acetate tablets +3 more
    PhaseNot recorded
    Registry statusRecruiting

  • Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

    NCT02835508 · start 2016-06

    Registered record
    Registry ID
    NCT02835508
    Conditions
    Healthy
    Interventions
    JNJ-56021927 60 Milligram; JNJ-56021927 120 Milligram; JNJ-56021927 240 Milligram
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06
    Completion
    2016-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionJNJ-56021927 60 Milligram; JNJ-56021927 120 Milligram; JNJ-56021927 240 Milligram
    PhasePhase 1
    Registry statusCompleted

  • Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

    NCT02703623 · start 2016-05-18

    Registered record
    Registry ID
    NCT02703623
    Conditions
    Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7
    Interventions
    Abiraterone Acetate; Apalutamide; Cabazitaxel; Carboplatin; Ipilimumab; Laboratory Biomarker Analysis; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-05-18
    Completion
    2028-03-31
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; PSA Progression +1 more
    InterventionAbiraterone Acetate; Apalutamide; Cabazitaxel; Carboplatin +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

    NCT02106507 · start 2014-04

    Registered record
    Registry ID
    NCT02106507
    Conditions
    Prostate Cancer
    Interventions
    apalutamide; Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04
    Completion
    2021-06-28
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionapalutamide; Everolimus
    PhasePhase 1
    Registry statusCompleted

  • Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

    NCT01792687 · start 2013-02-05

    Registered record
    Registry ID
    NCT01792687
    Conditions
    Prostate Cancer
    Interventions
    ARN-509; Abiraterone acetate; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-02-05
    Completion
    2024-02-13
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionARN-509; Abiraterone acetate; Prednisone
    PhasePhase 1
    Registry statusCompleted